Caroline Letson’s Post

PUBLICATION: Here’s a great paper on the Journal of Clinical #Oncology (with CDI Labs CSO, Tyler Hulett) highlighting how our #HuProt™ protein #microarray demonstrated the potential to predict and mitigate severe immune-related adverse events (#irAEs) that may cause patients to withdraw from their treatment. With HuProt assays, we’re providing a unique capability that could help clinicians optimize #immunotherapy delivery, enhance patient selection, and prevent irAEs that may lead to treatment suppression. Studies like this exemplify the remarkable potential of #antibody #seromics in personalized immunotherapy. https://lnkd.in/dDJirM-t

🌍 On Lung Cancer Awareness Month, let's reflect on the importance of raising awareness and supporting research in this area. Lung cancer remains one of the leading causes of death worldwide. 🔬 HAWK Biosystems is committed to research and exploring more precise ways to approach immunotherapy, with the potential to significantly improve responses and survival. 🌟 These advancements aim not only to enhance the treatment landscape but also to optimize investments for more effective outcomes. 🔍 Current research could change the game in the fight against lung cancer, offering hope to those battling this disease. 🏥 Very soon our technology will contribute to this advancement in lung cancer treatment. Read more: https://lnkd.in/eJpGCmz4 Together, we move towards a future with better responses to lung cancer. Join the fight!

Shortage of oncologists is a reality, not a forecast: 2022 Snapshot: State of the Oncology Workforce in America | JCO Oncology Practice (ascopubs.org) I am one of the 21% oncologists who left practice between 2015-2022. Without knowing, I was part of the problem, not the solution. Profile of the Oncology Physician Workforce and the Characteristics of Attrition | JCO Oncology Practice (ascopubs.org) We need to secure a robust oncology workforce to care for an increasing number of patients, as the population ages and the number of cancer survivors increase. How? Oncologists are leaving practices for several reasons, but burnout, hospital mergers, and monopoly of working conditions are key. Rural community practices are particularly affected. Pandemic didn't help either. To retain oncologists in rural communities, think about hybrid academic-community training programs: Training Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the Future | JCO Oncology Practice (ascopubs.org). Most importantly: oncologists, like other healthcare professionals, have to break the shackles from hospital conglomerates and be able to negotiate contracts that include salary, quality of care versus quantity, and better work life-balance. Otherwise, more cases like me will follow. And belive me, I am happier now than in my previous academic position.

Schedule a meeting with the experts from Discovery Life Sciences at #ASCO24

We are thrilled to share a recording of a GlycoNet webinar featuring Dr. Paula Videira, Co-Founder of CellmAbs, Co-director of GLYCOTwinning, and Associate Professor at Faculdade de Ciências e Tecnologia da Universidade NOVA de Lisboa. Introduced by Mr. David Firer, Chair of the GlycoNet Trainee Association – Executive Committee, Dr. Videira dives deep into "Unlocking the Glycoimmune Potential: Novel Strategies for Advanced Immunotherapy". Additionally, don’t miss the insightful presentation by her PhD student, Ms. Rita Adubeiro Lourenço, on "Deciphering the Enigmatic Role of O-glycan Signatures in Cancer". 👉 Watch the full recording here: https://lnkd.in/drFNUuS2 Learn more about GlycoNet and GLYCOTwinning and join us in advancing the field of glycomics and immunotherapy. #GlycoNet #GLYCOTwinning #Glycomics #glycobiology #CancerResearch #Glycoscience #Webinar

Springer Healthcare's official partnership with #ASCO is one of my favourite things about working here. Official ASCO content + Springer-led expert commentary is one of the things our learners value about our accredited programs. AND it means both Springer Nature and ASCO can co-market to reach both our audiences #CME #IME #NSCLC #oncology #meded #medicaleducation #independentmedicaleducation #SpringerHealthcareIME

https://lnkd.in/eMR8YV74 Incredible paper - thank you to the authors who published this. I still find it challenging determining the optimal use of adjuvant pembro in TNBC. What do you do in your practice?

In this video, Dr. Brian Sworder discusses the objective, methodology, and key results for one of the studies presented at the American Society of Hematology (#ASH) Annual Conference in 2023. The study shows the #utility of our proprietary technology, PhasED-Seq™ #MRD, vs. PET/CT to predict response following #curative intent induction #therapy in patients with diffuse large B-cell lymphoma (#DLBCL). #ForesightDx's ultra-sensitive liquid biopsy platform, Foresight CLARITY™ , is powered by PhasED-Seq™. Watch video here: https://t.ly/tyKgX Learn more about Foresight CLARITY here: https://t.ly/UnwGW #ForesightCLARITY #PhasEDseq #ctDNA #MRD #PrecisionMedicine #LiquidBiopsy

Lung nodules - not an uncommon source of angst amongst doctors & patients as one always wonders if it’s benign or malignant. The article highlights how common it is in Western Europe. I reckon it might be more common in Asia, given the highest prevalence of infections as well as nodule-mimics like granulomas. Something to consider as we advocate for more low-dose CT scans to screen for lung cancer. In the absence of blood tests and other biomarkers, there isn’t much more than can be done besides to watch and wait - if it’s of a small size, CT scans over a period of time help ascertain if further intervention is warranted. https://lnkd.in/g6yneMTa

Don't miss our interview with Sanjay Juneja, M.D. We're covering several important topics: 1. How to catch cancer much earlier to "live long and prosper!" 2. Why current diagnostics, including genomic testing, fall short of finding the best therapy for you. 3. How the SAGE Oncotest can help you to receive the most effective treatment. https://lnkd.in/g9AAuH8v